

Sanofi  
Form 6-K  
June 17, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

---

**For the month of June 2014**

**Commission File Number: 001-31368**

**SANOFI**

(Translation of registrant's name into English)

**54, rue La Boétie, 75008 Paris, FRANCE**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

## Edgar Filing: Sanofi - Form 6-K

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If  Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

## Edgar Filing: Sanofi - Form 6-K

In June 2014, Sanofi issued the statements attached hereto as Exhibits 99.1 to 99.3 which are incorporated herein by reference.

### Exhibit List

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.1	Press release dated June 12, 2014: Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR
Exhibit 99.2	Press release dated June 14, 2014: Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes
Exhibit 99.3	Press release dated June 14, 2014: Sanofi Reports Positive Phase 3 Results for Toujeo®

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 17, 2014

SANOFI

By	/S/ John Felitti	
	Name:	John Felitti
	Title:	Associate Vice President, Corporate Law, Financial & Securities Law

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.1	Press release dated June 12, 2014: Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR
Exhibit 99.2	Press release dated June 14, 2014: Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes
Exhibit 99.3	Press release dated June 14, 2014: Sanofi Reports Positive Phase 3 Results for Toujeo®